|
@ScripMandy | |||||
|
SVB Leerink’s Cavazos says crossover VC rounds that bring in future IPO investors to companies are not going away. They used to be a nice to how & now a must have. Companies that do crossover rounds do better in their IPOs. #BiotechShowcase
|
||||||
|
||||||
|
Mandy Jackson
@ScripMandy
|
15. sij |
|
Spending some time this afternoon at the #BiotechShowcase (or so you might have heard). Looking forward to the Lunch Plenary: “Mega A-Rounds, Mega IPOs and consolidation”
|
||
|
|
||
|
Mandy Jackson
@ScripMandy
|
15. sij |
|
Gabriel Cavazos of SVB Leerink said there still are a lot of high quality companies filing for IPOs, but the general consensus is that the best time to go public in 2020 is during the first half of the year due to election risk. #BiotechShowcase
|
||
|
|
||
|
Mandy Jackson
@ScripMandy
|
15. sij |
|
@pharmaprodigy notes typically there are half as many IPOs in an election year. #BiotechShowcase
|
||
|
|
||
|
Mandy Jackson
@ScripMandy
|
15. sij |
|
Jeanne Cunicelli of UPMC Enterprises says they’d like to be part of big VC rounds, but only for the right companies. Notes that smaller rounds are just right-sized for those companies. #BiotechShowcase
|
||
|
|
||